Grundlæggende statistik
| LEI | 549300CSHW546WORC082 |
| CIK | 736822 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Immucor Inc
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| July 25, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 333-178102 Immucor, Inc. (Exact name of registrant as specified in its char |
|
| July 18, 2017 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2017 IMMUCOR, INC. (Exact Name of Registrant as Specified in its Charter) Georgia 0-14820 22-2408354 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Id |
|
| July 18, 2017 |
Immucor, Inc. Announces Results of Exchange Offer Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770.441.2051 Immucor, Inc. Announces Results of Exchange Offer July 18, 2017 NORCROSS, Ga., July 18, 2017 Immucor, Inc. (the ?Company? or ?Immucor?) today announced the expiration of an offer to eligible holders to exchange up to a maximum aggregate principal amount of $390 million of Immucor?s outstanding 11.125% Senior Notes due 2019 (th |
|
| June 23, 2017 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2017 IMMUCOR, INC. (Exact Name of Registrant as Specified in its Charter) Georgia 0-14820 22-2408354 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| June 21, 2017 |
Certain Information Provided to Prospective Debt Financing Sources Exhibit 99.1 Certain Information Provided to Prospective Debt Financing Sources Proposed Refinancing As part of a proposed refinancing of Immucor Inc., we are seeking to extend the maturity of our senior secured term loan facility from August 19, 2018 to June 15, 2021 and to increase the principal amount from $635 million to $647 million. Transfusion and Transplant Markets Based on our estimates, |
|
| June 21, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2017 IMMUCOR, INC. (Exact Name of Registrant as Specified in its Charter) Georgia 0-14820 22-2408354 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Id |
|
| June 20, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 19, 2017 IMMUCOR, INC. (Exact Name of Registrant as Specified in its Charter) Georgia 0-14820 22-2408354 (State or Other Jurisdiction of (Commission File Number) (IRS Employer Id |
|
| June 20, 2017 |
IMMUCOR, INC. ANNOUNCES EXCHANGE OFFER Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770.441.2051 IMMUCOR, INC. ANNOUNCES EXCHANGE OFFER NORCROSS, Ga., June 19, 2017 ? Immucor, Inc. (the ?Company? or ?Immucor?) announced the commencement of an offer to eligible holders to exchange any and all of Immucor?s outstanding 11.125% Senior Notes due 2019 (the ?Old Notes?) for a new series of 11.125% Senior Notes due 2022 (the ?New |
|
| April 19, 2017 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2017 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| April 11, 2017 |
BLUD / Immucor Inc FORM 10-Q (Quarterly Report) FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2017 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 17, 2017 |
BLUD / Immucor Inc 10-Q - Quarterly Report - FORM 10-Q FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2016 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| October 17, 2016 |
BLUD / Immucor Inc 10-Q - Quarterly Report - FORM 10-Q blud2016083010q.htm FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2016 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact nam |
|
| August 22, 2016 |
EX-21 2 ex21.htm EXHIBIT 21 Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S.p.A. Italy Immucor Diagnosticos Medicos Lda. Portugal Dominion Biologicals Limited Canada Immucor, S.L. Spain Immucor Gamma Benelux SPRL Belgium Immucor K. K. Japan Immucor France S.A.S. France IBG Immucor Limited United Kingdom Bio |
|
| August 22, 2016 |
EX-21 2 ex21.htm EXHIBIT 21 Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S.p.A. Italy Immucor Diagnosticos Medicos Lda. Portugal Dominion Biologicals Limited Canada Immucor, S.L. Spain Immucor Gamma Benelux SPRL Belgium Immucor K. K. Japan Immucor France S.A.S. France IBG Immucor Limited United Kingdom Bio |
|
| August 22, 2016 |
BLUD / Immucor Inc 10-K - Annual Report - FORM 10-K blud2016053110k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2016 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMU |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2016 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) Fi |
|
| May 10, 2016 |
AMENDMENT NO. 6 TO THE CREDIT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 6 TO THE CREDIT AGREEMENT AMENDMENT NO. 6, dated as of May 4, 2016 (this “Amendment”), by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantors, the Revolving Credit Lenders, and CITIBANK, N.A., as administrative agent (in such cap |
|
| April 11, 2016 |
BLUD / Immucor Inc 10-Q - Quarterly Report - FORM 10-Q blud2016022910q.htm FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 29, 2016 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact n |
|
| January 13, 2016 |
BLUD / Immucor Inc 10-Q - Quarterly Report - FORM 10-Q blud2015113010q.htm FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2015 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact n |
|
| December 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2015 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 15, 2015 |
AMENDMENT NO. 5 TO THE CREDIT AGREEMENT EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 AMENDMENT NO. 5 TO THE CREDIT AGREEMENT AMENDMENT NO. 5, dated as of December 9, 2015 (this “Amendment”), by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantors, the Revolving Credit Lenders party hereto, and CITIBANK, N.A., as administrative |
|
| October 13, 2015 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2015 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as s |
|
| August 21, 2015 |
EX-21 3 ex21.htm EXHIBIT 21 Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S.p.A. Italy Immucor Diagnosticos Medicos Lda. Portugal Dominion Biologicals Limited Canada Immucor, S.L. Spain Immucor Gamma Benelux SPRL Belgium Immucor K. K. Japan Immucor France S.A.S. France IBG Immucor Limited United Kingdom Bio |
|
| August 21, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2015 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact nam |
|
| August 21, 2015 |
Exhibit 10.19 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (?Agreement?), dated as of June 9, 2015 is made by and between Immucor, Inc., a Georgia corporation (the ?Company?), IVD Holdings Inc., a Delaware corporation (?Parent?) and Jeffrey R. Binder (the ?Executive?). WHEREAS, the Company desires that the Executive serve the Company as its Chief Executive Officer, on the terms |
|
| July 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2015 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| July 2, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2015 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| July 2, 2015 |
Jeffrey R. Binder Appointed President and CEO of Immucor Exhibit 99.1 Jeffrey R. Binder Appointed President and CEO of Immucor Norcross, Georgia ? June 29, 2015? Immucor, Inc., a global leader in transfusion and transplantation diagnostics and a portfolio company of global private investment firm TPG, today announced the appointment of Jeffrey R. Binder (?Jeff?) as President, Chief Executive Officer and Chairman of the Board of Directors. Binder succeed |
|
| April 10, 2015 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2015 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 13, 2015 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| October 10, 2014 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 10-Q 1 blud2014083110q.htm FORM 10-Q FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR |
|
| October 10, 2014 |
IVD Holdings Inc. 2011 Equity Incentive Plan Amendment to Non-statutory Stock Option Agreement Exhibit 10.1 Name of Optionee: [?] Date of Amendment: [?] Number of Unvested Tranche 2 Options: [?] IVD Holdings Inc. 2011 Equity Incentive Plan Amendment to Non-statutory Stock Option Agreement This amendment (the ?Amendment?) to the Non-Statutory Stock Option Agreement (the ?Agreement?) by and between IVD Holdings Inc. (the ?Company?) and the optionee set forth above (the ?Optionee?) is made as |
|
| August 26, 2014 |
EX-21 4 ex21.htm EXHIBIT 21 Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S.p.A. Italy Immucor Diagnosticos Medicos Lda. Portugal Dominion Biologicals Limited Canada Immucor, S.L. Spain Immucor Gamma Benelux SPRL Belgium Immucor K. K. Japan Immucor France S.A.S. France IBG Immucor Limited United Kingdom Bio |
|
| August 26, 2014 |
3130 Building 37,931 rsf 3150 Building 15,759 rsf 7000 Building 14,307 rsf Exhibit 10.12-2 LEASE This LEASE (this ?Lease?), is made and entered into effective as of the 1st day of August, 2013 (the ?Effective Date?), by and between KENNESAW WALL I, LLC, a Delaware limited liability company (?Landlord?), and IMMUCOR, INC., a Georgia corporation (?Tenant?). I. GENERAL. 1.1 Consideration. Landlord enters into this Lease in consideration of the payment by Tenant of the rents |
|
| August 26, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2014 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact nam |
|
| August 26, 2014 |
SEVENTH AMENDMENT TO OFFICE LEASE AGREEMENT Exhibit 10.12-1 SEVENTH AMENDMENT TO OFFICE LEASE AGREEMENT THIS SEVENTH AMENDMENT TO OFFICE LEASE AGREEMENT (?Amendment?) is made and entered into as of the 1st day of July, 2013 (the ?Effective Date?), by and between MLCFC 2007-7 NORCROSS PARK LIMITED PARTNERSHIP, a Georgia limited partnership (?Landlord?), and IMMUCOR, INC., a Georgia corporation (?Tenant?). W I T N E S S E T H: WHEREAS, Tenant |
|
| June 3, 2014 |
Financial Statements and Exhibits, Other Events blud201406038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2014 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer |
|
| June 3, 2014 |
Immucor Announces Lifting of FDA NOIR ex99-1.htm Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770.441.2051 Immucor Announces Lifting of FDA NOIR NORCROSS, Ga., June 2, 2014 – Immucor, Inc., a global leader in transfusion and transplantation diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that the Notice of Intent to Revoke (“NOIR”) has been lifted. “We take our commi |
|
| April 14, 2014 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2014 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 13, 2014 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| October 15, 2013 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as s |
|
| August 26, 2013 |
UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION Exhibit 10.19 UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF GEORGIA ATLANTA DIVISION IN RE IMMUCOR, INC. SECURITIES LITIGATION Civil Action No. 1:09-cv-2351-TWT STIPULATION AND AGREEMENT OF SETTLEMENT This Stipulation of Settlement (the ?Stipulation?) is entered into between and among the following Settling Parties (as defined in section 1 below) by and through their respective counsel |
|
| August 26, 2013 |
[Remainder of page intentionally left blank.] Exhibit 10.14 December 12, 2011 William Hawkins 2650 Marshland Road Wayzata, MN 55391 Dear Bill, In connection with your service as Chief Executive Officer of Immucor, Inc. and IVD Holdings Inc. (collectively, the ?Company?), TPG Capital, L.P. (?TPG?) wishes to enter into a side letter agreement with you regarding certain matters relating to your service with certain companies affiliated with TPG, |
|
| August 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact nam |
|
| August 26, 2013 |
Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S. |
|
| August 12, 2013 |
blud201308128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employe |
|
| August 12, 2013 |
IMMUCOR, INC. ANNUAL BONUS PLAN EX-10 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 IMMUCOR, INC. ANNUAL BONUS PLAN SECTION 1. PURPOSE. This annual bonus plan (the “Plan”) is applicable to those employees of Immucor, Inc. (the “Company”) and its subsidiaries who are executive officers of the Company, as well as certain other employees of the Company specified by the Compensation Committee (the “Committee”) of the Board of Directors (th |
|
| April 12, 2013 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2013 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| March 22, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K blud201303218k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employe |
|
| March 22, 2013 |
Immucor Completes Acquisition of LIFECODES® Business from Hologic, Inc. blud201303218kex99-1.htm Exhibit 99.1 3130 GATEWAY DRIVE / P.O. BOX 5625 NORCROSS, GA 30091-5625 1.855.IMMUCOR PHONE www.immucor.com WEB FOR IMMEDIATE RELEASE IMMUCOR CONTACT: Michele Howard, Vice President of Corporate Development and Communications 770.441.2051 Immucor Completes Acquisition of LIFECODES® Business from Hologic, Inc. NORCROSS, Ga., March 22, 2013 – Immucor, Inc., a global leader i |
|
| February 22, 2013 |
AMENDED AND RESTATED AMENDMENT NO. 2 Exhibit 10.1 AMENDED AND RESTATED AMENDMENT NO. 2 AMENDED AND RESTATED AMENDMENT NO. 2, dated as of February 19, 2013 (this “Amendment”), by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantor, CITIGROUP GLOBAL MARKETS INC., AND J.P. MORGAN SECURITIES LLC (collectively, the “Lead Arrangers” |
|
| February 22, 2013 |
AMENDMENT NO. 3 TO THE CREDIT AGREEMENT AND AMENDMENT NO. 1 TO THE GUARANTY Exhibit 10.2 AMENDMENT NO. 3 TO THE CREDIT AGREEMENT AND AMENDMENT NO. 1 TO THE GUARANTY AMENDMENT NO. 3, dated as of February 19, 2013, by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantor, CITIGROUP GLOBAL MARKETS INC., J.P. MORGAN SECURITIES LLC AND UBS SECURITIES LLC (collectively, th |
|
| February 22, 2013 |
AMENDMENT NO. 4 TO THE CREDIT AGREEMENT Exhibit 10.3 AMENDMENT NO. 4 TO THE CREDIT AGREEMENT AMENDMENT NO. 4, dated as of February 19, 2013, by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantor, CITIGROUP GLOBAL MARKETS INC., J.P. MORGAN SECURITIES LLC AND UBS SECURITIES LLC (collectively, the “Lead Arrangers”), and CITIBANK, N |
|
| February 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 31, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 31, 2013 |
Exhibit 10.1 AMENDMENT NO. 2 AMENDMENT NO. 2, dated as of January 25, 2013 (this “Amendment”), by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantor, CITIGROUP GLOBAL MARKETS INC., AND J.P. MORGAN SECURITIES LLC (collectively, the “Lead Arrangers”), and CITIBANK, N.A., as administrative ag |
|
| January 16, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| January 14, 2013 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2012 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2013 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| January 9, 2013 |
3130 GATEWAY DRIVE / P.O. BOX 5625 NORCROSS, GA 30091-5625 1.855.IMMUCOR PHONE www.immucor.com WEB Exhibit 99.1 3130 GATEWAY DRIVE / P.O. BOX 5625 NORCROSS, GA 30091-5625 1.855.IMMUCOR PHONE www.immucor.com WEB FOR IMMEDIATE RELEASE IMMUCOR CONTACT: Michele Howard, Vice President of Corporate Development and Communications 770.441.2051 Immucor to Acquire the LIFECODES® Business from Hologic, Inc. Combines best-in-class transfusion diagnostics and best-in-class transplantation diagnostics NORCRO |
|
| January 9, 2013 |
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT among: Immucor, Inc., a Georgia corporation; and Gen-Probe Incorporated, a Delaware corporation Dated as of January 3, 2013 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement is entered into as of January 3, 2013, by and among Immucor, Inc., a Georgia corporation (the “Purchaser”), and Gen-Probe Incorporated, a Delaware co |
|
| October 10, 2012 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2012 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as s |
|
| August 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2012 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| August 24, 2012 |
Exhibit 10.1 AMENDMENT NO. 1 AMENDMENT NO. 1, dated as of August 21, 2012 (this “Amendment”), by and among IMMUCOR, INC., a Georgia corporation (the “Borrower”), IVD INTERMEDIATE HOLDINGS B INC., a Delaware corporation (“Holdings”), the Subsidiary Guarantor, CITIGROUP GLOBAL MARKETS INC., J.P. MORGAN SECURITIES LLC, AND UBS SECURITIES LLC (collectively, the “Lead Arrangers”), and CITIBANK, N.A., a |
|
| July 27, 2012 |
Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S. |
|
| July 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2012 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact nam |
|
| July 27, 2012 |
IMMUCOR, INC. KEY EMPLOYEE SEVERANCE PLAN ARTICLE 1 PURPOSE AND TERM EX-10.15 3 ex10-15.htm EXHIBIT 10.15 Exhibit 10.15 IMMUCOR, INC. KEY EMPLOYEE SEVERANCE PLAN ARTICLE 1 PURPOSE AND TERM 1.1 Purpose. IVD Holdings Inc. (“Holdings”) has adopted this Immucor, Inc. Key Employee Severance Plan (the “Plan”), for the benefit of certain employees of Immucor, Inc. (the “Company”), on the terms and conditions hereinafter stated. 1.2 Term. The Plan shall generally be effect |
|
| July 27, 2012 |
EX-10.9 2 ex10-9.htm EXHIBIT 10.9 Exhibit 10.9 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30071 (herein referred to as the “Company”), and Patrick D. Waddy (herein referred to as “Employee”). The parties hereto desire to enter into a |
|
| April 11, 2012 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 29, 2012 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant |
|
| April 11, 2012 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF IMMUCOR, INC. [Amended and Restated as of April 4, 2012] ARTICLE I LAW, ARTICLES OF INCORPORATION AND BYLAWS These Bylaws are subject to the Articles of Incorporation of the Corporation. In these Bylaws, references to law, the Articles of Incorporation and Bylaws mean the law, the provisions of the Articles of Incorporation and the Bylaws as from time to |
|
| April 11, 2012 |
Exhibit 10.5 April 10, 2012 Mr. Dominique Petitgenet 690 Wednesbury Road Alpharetta, GA 30022 Dear Dominique: Thank you for your interest regarding career opportunities at Immucor. We believe that your background and experience represent a compelling match with our needs and would like to tender an offer of employment to you. Your position will be Vice President and Chief Financial Officer reporti |
|
| February 27, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2012 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| February 13, 2012 |
BLUD / Immucor Inc / WESTFIELD CAPITAL MANAGEMENT CO LP - AMENDMENT NO. 2 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Immucor, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 452526106 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 13, 2012 |
Exhibit 99.1 Summary of Lawsuits 1. The following lawsuits were originally filed in the districts listed below. All of the cases filed outside of the Eastern District of Pennsylvania, except that filed by Ivy Creek of Tallapoosa, LLC, d/b/a Lake Martin Community Hospital, were subsequently transferred to the United States District Court for the Eastern District of Pennsylvania pursuant to orders e |
|
| January 13, 2012 |
Quarterly Report Pursuant to Section 13 or 15(d) FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2011 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 13, 2012 |
IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA Exhibit 10.4 IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA ) IN RE: BLOOD REAGENTS ANTITRUST ) LITIGATION ) MDL Docket No. 09-2081 ) ) HON. JAN E. DUBOIS THIS DOCUMENT RELATES TO ALL ) ACTIONS ) ) SETTLEMENT AGREEMENT FOR IMMUCOR, INC. This Settlement Agreement ("Settlement Agreement") is made and entered into this 11th day of January (the "Execution Date"), by and b |
|
| December 14, 2011 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-178102 PROSPECTUS IMMUCOR, INC. OFFER TO EXCHANGE $400,000,000 aggregate principal amount of its 11.125% Senior Notes due 2019, the issuance of which has been registered under the Securities Act of 1933, as amended, for all of its outstanding 11.125% Senior Notes due 2019 We are offering to exchange, upon the terms and subject |
|
| December 12, 2011 |
Acceleration Request December 12, 2011 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| December 9, 2011 |
EX-10.12 3 d255293dex1012.htm FORM OF MANAGEMENT STOCKHOLDERS' AGREEMENT Exhibit 10.12 FORM OF MANAGEMENT STOCKHOLDERS’ AGREEMENT by and among IVD Holdings Inc., Immucor, Inc. and the Investors and Managers Named Herein Dated as of TABLE OF CONTENTS 1. EFFECTIVENESS; DEFINITIONS 2 1.1. Effective Date 2 1.2. Definitions 2 2. VOTING AGREEMENT 2 2.1. Election of Directors 2 2.2. Significant Transacti |
|
| December 9, 2011 |
Exhibit 10.11 Execution Version EMPLOYMENT AGREEMENT AGREEMENT, effective as of October 17, 2011 (the ?Agreement?), between Immucor, Inc. (?Immucor?), IVD Holdings Inc. (?Parent,? and together with Immucor, the ?Company?), and William Hawkins (the ?Executive?). WHEREAS, the Company desires that the Executive serve the Company as its Chief Executive Officer, on the terms and conditions set forth he |
|
| December 9, 2011 |
As filed with the Securities and Exchange Commission on December 9, 2011 As filed with the Securities and Exchange Commission on December 9, 2011 Registration No. |
|
| December 7, 2011 |
SEC Letter 3130 Gateway Drive Norcross, Georgia 30071 (770) 441-2051 December 7, 2011 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| November 22, 2011 |
EX-4.1 4 d255293dex41.htm INDENTURE Exhibit 4.1 INDENTURE Dated as of August 19, 2011 Between IVD Acquisition Corporation, to be merged with and into Immucor, Inc., and DEUTSCHE BANK TRUST COMPANY AMERICAS, as Trustee 11.125% SENIOR NOTES DUE 2019 1 CROSS-REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.10 (b) 7.03; 7.10 (c) |
|
| November 22, 2011 |
Registration Rights Agreement Exhibit 4.4 Registration Rights Agreement This REGISTRATION RIGHTS AGREEMENT, dated August 19, 2011 (this “Agreement”), is entered into by and between IVD Acquisition Corporation, a Georgia corporation (the “Company”) and J.P. Morgan Securities LLC (“J.P. Morgan”), as representative of the several initial purchasers listed in Schedule 1 to the Purchase Agreement (as d |
|
| November 22, 2011 |
EX-10.2 11 d255293dex102.htm SECURITY AGREEMENT Exhibit 10.2 SECURITY AGREEMENT dated as of August 19, 2011 among IVD ACQUISITION CORPORATION, which on the Closing Date shall be merged with and into IMMUCOR, INC., with Immucor, Inc. surviving such merger as the Borrower, IVD INTERMEDIATE HOLDINGS B INC. as Holdings, THE SUBSIDIARY GUARANTORS PARTY HERETO FROM TIME TO TIME, and CITIBANK, N.A., as A |
|
| November 22, 2011 |
As filed with the Securities and Exchange Commission on November 21, 2011 Table of Contents As filed with the Securities and Exchange Commission on November 21, 2011 Registration No. |
|
| November 22, 2011 |
Amended and Restated By-Laws of BioArray Solutions Ltd. Exhibit 3.2.2 AMENDED AND RESTATED BYLAWS OF BIOARRAY SOLUTIONS LTD. (a Delaware Corporation) TABLE OF CONTENTS ARTICLE 1: DEFINITIONS 1 1.1 Definitions 1 ARTICLE 2: STOCK CERTIFICATES 1 2.1 Stock Certificates 1 2.2 List of Stockholders 1 2.3 Transfers of Stock 2 2.4 Lost Certificates 2 ARTICLE 3: STOCKHOLDERS’ MEETINGS 2 3.1 Annual Meetings |
|
| November 22, 2011 |
Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) DEUTSCHE BANK TRUST COMPANY AMERICAS (formerly BANKERS TRUST COMPANY) (Exact name of trustee as specifi |
|
| November 22, 2011 |
Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S. |
|
| November 22, 2011 |
Exhibit 10.1 Published CUSIP Number: 45252HAA0 Deal Published CUSIP Number: 45252HAB8 Term Published CUSIP Number: 5252HAC6 Dollar Revolver Published CUSIP Number: 45252HAD4 Alternative Currency Revolver $715,000,000 CREDIT AGREEMENT Dated as of August 19, 2011 among IVD ACQUISITION CORPORATION, which on the Closing Date shall be merged with and into IMMUCOR, INC., with Immucor, Inc. surviving suc |
|
| November 22, 2011 |
EX-4.2 5 d255293dex42.htm SUPPLEMENTAL INDENTURE Exhibit 4.2 SUPPLEMENTAL INDENTURE Supplemental Indenture (this “Supplemental Indenture”), dated as of August 19, 2011 among Immucor, Inc., a Georgia corporation (the “Issuer”), BioArray Solutions Ltd., a Delaware corporation (the “Guarantor”) and Deutsche Bank Trust Company Americas, a New York banking corporation, as trustee (the “Trustee”). W I T |
|
| November 22, 2011 |
Computation of Ratio of Earnings to Fixed Charges Exhibit 12 Computation of Ratio of Earnings to Fixed Charges Predecessor Combined Pro forma Fiscal Year Ended May 31, Quarter Ended Fiscal Year Ended Quarter Ended 2007 2008 2009 2010 2011 August 31, 2011 May 31, 2011 August 31, 2011 (in millions) Earnings: Net income before taxes $ 94. |
|
| November 22, 2011 |
EX-99.1 18 d255293dex991.htm FORM OF LETTER OF TRANSMITTAL Exhibit 99.1 IMMUCOR, INC. LETTER OF TRANSMITTAL OFFER TO EXCHANGE UP TO $400,000,000 AGGREGATE PRINCIPAL AMOUNT OF ITS 11.125% SENIOR NOTES DUE 2019, THE ISSUANCE OF WHICH HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, FOR ALL OF ITS OUTSTANDING 11.125% SENIOR NOTES DUE 2019 THE EXCHANGE OFFER AND WITHDRAWAL RIGHTS WILL |
|
| November 22, 2011 |
Exhibit 99.2 NOTICE OF GUARANTEED DELIVERY FOR OFFER TO EXCHANGE UP TO $400,000,000 PRINCIPAL AMOUNT OF ITS 11.125% SENIOR NOTES DUE 2019, THE ISSUANCE OF WHICH HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, FOR ALL OF ITS OUTSTANDING 11.125% SENIOR NOTES DUE 2019 IMMUCOR, INC. THE EXCHANGE OFFER AND WITHDRAWAL RIGHTS WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON , 2011 (THE |
|
| November 22, 2011 |
Exhibit 10.3 GUARANTY dated as of August 19, 2011 among IVD INTERMEDIATE HOLDINGS B INC., as Holdings, THE OTHER GUARANTORS PARTY HERETO FROM TIME TO TIME, and CITIBANK, N.A., as Administrative Agent TABLE OF CONTENTS Page ARTICLE I Definitions 1 Credit Agreement Definitions 1 Other Defined Terms 1 ARTICLE II Guarantee 2 Guarantee 2 Guarantee of Payment 2 No Limitations 3 Reinstatement 4 Agreement |
|
| November 22, 2011 |
Exhibit 10.4 EXECUTION VERSION MANAGEMENT SERVICES AGREEMENT This Management Services Agreement (this ?Agreement?) is entered into as of August 19, 2011 by and among IVD Acquisition Corporation, a Georgia corporation (?Merger Sub?), IVD Intermediate Holdings A Inc., a Delaware corporation (?Intermediate Holdings A?), IVD Intermediate Holdings B Inc., a Delaware corporation (?Intermediate Holdings |
|
| November 22, 2011 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION BIOARRAY SOLUTIONS LTD. EX-3.1.2 2 d255293dex312.htm AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Exhibit 3.1.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BIOARRAY SOLUTIONS LTD. FIRST: The name of the corporation is BIOARRAY SOLUTIONS LTD. SECOND: The address of the registered office of the corporation in the State of Delaware is 1209 Orange Street in the City of Wilmington, County of New Castle. The name |
|
| November 22, 2011 |
Registration Rights Agreement Exhibit 4.5 J.P. Morgan Securities LLC As Representative of the several Initial Purchasers listed in Schedule 1 to the Purchase Agreement (as defined herein) c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Reference is made to the Purchase Agreement (the “Purchase Agreement”), dated August 16, 2011, between (i) IVD Acqu |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 0-14820 IMMUCOR, INC. (Exact name of registrant as specified in its c |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 29, 2011 |
As filed with the Securities and Exchange Commission on August 29, 2011 As filed with the Securities and Exchange Commission on August 29, 2011 Registration No. |
|
| August 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 25, 2011 |
IVD ACQUISITION CORPORATION SUCCESSFULLY COMPLETES ACQUISITION OF IMMUCOR Exhibit 99.1 FOR IMMEDIATE RELEASE IVD ACQUISITION CORPORATION SUCCESSFULLY COMPLETES ACQUISITION OF IMMUCOR NORCROSS, GA & FORT WORTH, TX, August 19, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and TPG Capital, L.P. (?TPG Capital?) today announced the successful acquisition of the Company by IVD Acquisition Corporation, an affiliate of TPG Capital, for $27.00 per share in cash, or approxi |
|
| August 25, 2011 |
AMENDED AND RESTATED ARTICLES OF INCORPORATION IMMUCOR, INC. Exhibit 3.1 AMENDED AND RESTATED ARTICLES OF INCORPORATION OF IMMUCOR, INC. 1. The name of this corporation is Immucor, Inc. 2. The registered office of this corporation in the State of Georgia is located at 1201 Peachtree Street, N.E., Atlanta, GA 30361. The name of its registered agent at such address is CT Corporation System. 3. The total number of shares of stock that this corporation shall ha |
|
| August 25, 2011 |
AMENDED AND RESTATED BYLAWS IMMUCOR, INC. ARTICLE I LAW, ARTICLES OF INCORPORATION AND BYLAWS EX-3.2 3 dex32.htm AMENDED AND RESTATED BYLAWS OF IMMUCOR, INC. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF IMMUCOR, INC. ARTICLE I LAW, ARTICLES OF INCORPORATION AND BYLAWS These Bylaws are subject to the Articles of Incorporation of the Corporation. In these Bylaws, references to law, the Articles of Incorporation and Bylaws mean the law, the provisions of the Articles of Incorporation and the By |
|
| August 19, 2011 |
Amendment No. 10 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name o |
|
| August 19, 2011 |
IVD ACQUISITION CORPORATION SUCCESSFULLY COMPLETES ACQUISITION OF IMMUCOR Exhibit (a)(5)(J) FOR IMMEDIATE RELEASE IVD ACQUISITION CORPORATION SUCCESSFULLY COMPLETES ACQUISITION OF IMMUCOR NORCROSS, GA & FORT WORTH, TX, August 19, 2011 ? Immucor, Inc. |
|
| August 16, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 16, 2011 |
Amendment No.8 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of F |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 16, 2011 |
Amendment No.8 to SC 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 8) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securi |
|
| August 16, 2011 |
IMMUCOR ANNOUNCES END OF “GO-SHOP” PERIOD Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR ANNOUNCES END OF ?GO-SHOP? PERIOD NORCROSS, GA, August 16, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (?Immucor? or the ?Company?), today announced the expiration of the ?go-shop? period pursuant to the terms of the previously announced merger agreement, dated as of July 2, 2011, which contemplates the acquisition of the Company by an affiliate of TPG Capital, L |
|
| August 16, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF x THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2011 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUC |
|
| August 16, 2011 |
Amendment No. 9 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of |
|
| August 16, 2011 |
IMMUCOR ANNOUNCES END OF “GO-SHOP” PERIOD Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR ANNOUNCES END OF ?GO-SHOP? PERIOD NORCROSS, GA, August 16, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (?Immucor? or the ?Company?), today announced the expiration of the ?go-shop? period pursuant to the terms of the previously announced merger agreement, dated as of July 2, 2011, which contemplates the acquisition of the Company by an affiliate of TPG Capital, L |
|
| August 16, 2011 |
SCHEDULE 14D9 AMENDMENT #7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2011 |
Amendment No.7 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of F |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL Exhibit (a)(5)(H) FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE NORCROSS, GA & FORT WORTH, TX, August 4, 2011 ? Immucor, Inc. |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE Exhibit 99.2 FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE NORCROSS, GA & FORT WORTH, TX, August 4, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG Capital?), today announced that Germany?s Federal Cartel Office has granted clearance in connection with |
|
| August 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 4, 2011 |
Schedule 14D9 Amendment #6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2011 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD NORCROSS, GA & FORT WORTH, TX, August 3, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG Capital?), today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Ac |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE Exhibit 99.2 FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE GERMAN ANTITRUST AND MERGER CONTROL CLEARANCE NORCROSS, GA & FORT WORTH, TX, August 4, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG Capital?), today announced that Germany?s Federal Cartel Office has granted clearance in connection with |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD Exhibit (a)(5)(G) FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD NORCROSS, GA & FORT WORTH, TX, August 3, 2011 ? Immucor, Inc. |
|
| August 4, 2011 |
IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR AND IVD ACQUISITION CORPORATION ANNOUNCE EXPIRATION OF HSR WAITING PERIOD NORCROSS, GA & FORT WORTH, TX, August 3, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG Capital?), today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Ac |
|
| July 29, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 5) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 29, 2011 |
Amendment No. 6 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Na |
|
| July 29, 2011 |
Revised Preliminary Proxy Statement Table of Contents SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to Rule 14a-12 IMMUCOR, INC. |
|
| July 28, 2011 |
CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 EX-99.(B)(3) 5 dex99b3.htm AMENDED AND RESTATED COMMITMENT LETTER Exhibit (b)(3) EXECUTION COPY CITIGROUP GLOBAL MARKETS INC. 390 Greenwich Street New York, New York 10013 JPMORGAN CHASE BANK, N.A. 270 Park Avenue New York, NY 10017 UBS LOAN FINANCE LLC 677 Washington Boulevard Stamford, Connecticut 06901 J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, NY 10179 UBS SECURITIES LLC 299 Park |
|
| July 28, 2011 |
Amendment No.5 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of F |
|
| July 28, 2011 |
[remainder of the page intentionally left blank ? signature page follows] Exhibit (b)(1) EXECUTION VERSION July 2, 2011 IVD Holdings Inc. c/o TPG Capital, L.P. 345 California Street, Suite 3300 San Francisco, CA 94104 Ladies and Gentlemen: This letter agreement (this ?Agreement?) sets forth the commitment of TPG Partners VI, L.P., a Delaware limited partnership (the ?Fund?), subject to the terms and conditions contained herein, to purchase certain equity interests of IV |
|
| July 28, 2011 |
IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA Exhibit (a)(5)(F) IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA IRENE DIXON, On Behalf of Herself and All Others ) Similarly Situated. |
|
| July 28, 2011 |
Exhibit (b)(2) EXECUTION VERSION LIMITED GUARANTY LIMITED GUARANTY, dated as of July 2, 2011 (this ?Limited Guaranty?), by TPG Partners VI, L. |
|
| July 25, 2011 |
Amendment No.4 to the SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name |
|
| July 25, 2011 |
Exhibit (a)(5)(E) IN THE SUPERIOR COURT OF GWINNETT COUNTY STATE OF GEORGIA GILBERT ROSENTHAL, individually, and on behalf of all others similarly situated, Plaintiff, vs. |
|
| July 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 4) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 21, 2011 |
IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA EX-99.(A)(5)(D) 2 dex99a5d.htm COMPLAINT OF LARRY MACINTYRE Exhibit (a)(5)(D) IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA LARRY MACINTYRE, on behalf of himself and all others similarly situated, Civil Action No. 2011CV203397 Plaintiff, vs. CLASS ACTION COMPLAINT IMMUCOR, INC., TPG CAPITAL L.P., TPG PARTNERS VI, L.P., IVD HOLDINGS INC., JAMES F. CLOUSER, JOSHUA H. LEVINE, PAUL V. HOLLAN |
|
| July 21, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 21, 2011 |
Amendment No.3 to SC TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of F |
|
| July 20, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF X THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2011 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact nam |
|
| July 20, 2011 |
Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S. |
|
| July 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of Filing Persons (Parent of |
|
| July 19, 2011 |
IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA Exhibit (a)(5)(C) IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA ALAN PILLAY, On Behalf of Himself and All Others ) Similarly Situated. |
|
| July 18, 2011 |
Exhibit (a)(5)(B) IN THE SUPERIOR COURT OF GWINNETT COUNTY STATE OF GEORGIA BABETTE C. |
|
| July 18, 2011 |
Preliminary Proxy Statement Table of Contents SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to Rule 14a-12 IMMUCOR, INC. |
|
| July 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 18, 2011 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of Filing Persons |
|
| July 15, 2011 |
EX-99.(D)(2) 9 dex99d2.htm CONFIDENTIALITY AGREEMENT Exhibit (d)(2) May 27, 2011 CONFIDENTIAL TPG Capital, L.P. 301 Commerce Street Suite 3300 Fort Worth, TX 76102 Attention: Ronald Cami, Vice President Ladies and Gentlemen: TPG Capital, L.P., a Texas limited partnership (“TPG”), and Immucor, Inc., a Georgia corporation (“Immucor”), each have expressed interest in discussing steps that could lead |
|
| July 15, 2011 |
Exhibit (a)(1)(C) Offer To Purchase For Cash All Outstanding Shares of Common Stock of IMMUCOR, INC. |
|
| July 15, 2011 |
Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC. (Name of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly owned indirect subsidiary of IVD HOLDINGS INC. (Name of Filing Persons (Parent of Offer |
|
| July 15, 2011 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit (e)(21) Execution Copy AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT (this ?Agreement?), made and entered into as of this 10th day of June, 2011, by and between Immucor, Inc. |
|
| July 15, 2011 |
IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA Exhibit (a)(5) IN THE SUPERIOR COURT OF FULTON COUNTY STATE OF GEORGIA HILARY KRAMER, on Behalf of Herself and All Others Similarly Situated, Plaintiff, v. |
|
| July 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 15, 2011 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File |
|
| July 15, 2011 |
Exhibit (a)(1)(G) FOR IMMEDIATE RELEASE IVD ACQUISITION CORPORATION COMMENCES TENDER OFFER FOR ALL SHARES OF IMMUCOR, INC. |
|
| July 15, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE IVD ACQUISITION CORPORATION COMMENCES TENDER OFFER FOR ALL SHARES OF IMMUCOR, INC. Previously Announced Offer Price of $27.00 per Share in Cash NORCROSS, GA & FORT WORTH, TX, July 15, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG?), today announced that IVD Acquisition Corporation has |
|
| July 15, 2011 |
Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of IMMUCOR, INC. |
|
| July 15, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE IVD ACQUISITION CORPORATION COMMENCES TENDER OFFER FOR ALL SHARES OF IMMUCOR, INC. Previously Announced Offer Price of $27.00 per Share in Cash NORCROSS, GA & FORT WORTH, TX, July 15, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?) and IVD Acquisition Corporation, an affiliate of TPG Capital, L.P. (?TPG?), today announced that IVD Acquisition Corporation has |
|
| July 15, 2011 |
Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). |
|
| July 15, 2011 |
Exhibit (a)(1)(A) OFFER TO PURCHASE FOR CASH All Outstanding Shares of Common Stock of IMMUCOR, INC. |
|
| July 15, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Numb |
|
| July 15, 2011 |
Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of IMMUCOR, INC. |
|
| July 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| July 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| July 11, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Number of Class of Sec |
|
| July 6, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY TPG CAPITAL Immucor Shareholders to Receive $27.00 per Share in Cash; Fully Diluted Equity Value of $1.973 Billion NORCROSS, Ga., July 05, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the ?Company?), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announc |
|
| July 6, 2011 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR SECTION 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC. (Names of Subject Company) IVD ACQUISITION CORPORATION (Name of Filing Persons (Offeror)) a wholly-owned subsidiary of IVD HOLDINGS INC. (Name of Filing Persons (Parent of Offeror)) TPG Par |
|
| July 6, 2011 |
Exhibit 99.2 TPG Profile TPG Capital is one of the world?s leading private investment firms, with $48 billion of assets under management. The firm was founded in 1992 and is led by David Bonderman and Jim Coulter. TPG has extensive experience with global public and private investments executed through leveraged buyouts, recapitalizations, spinouts, growth investments, joint ventures and restructur |
|
| July 5, 2011 |
Exhibit 99.6 Senior Manager Talking Points What we announced: ? Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital. ? TPG Capital is a well-respected global investment company that seeks out well-managed, fundamentally solid businesses for long-term investments. Benefits of transaction: ? By partnering with TPG Capital, Immucor wi |
|
| July 5, 2011 |
AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDER RIGHTS AGREEMENT Exhibit 4.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 2 to Amended and Restated Shareholder Rights Agreement, which is effective on July 2, 2011 (the ?Amendment?), is between Immucor, Inc., a Georgia corporation (the ?Company?), and Computershare Trust Company, N.A. (the ?Rights Agent?). RECITALS: WHEREAS, the Board of Directors of the Company previous |
|
| July 5, 2011 |
Exhibit 99.3 Employee FAQ 1. What was announced today? Today we announced that our Board of Directors has approved the sale of Immucor to TPG Capital, a leading investment firm. We believe partnering with TPG Capital will help fuel Immucor?s growth and strengthen our leadership position in the global marketplace for transfusion medicine. 2. Who is TPG Capital? TPG Capital is a well-respected globa |
|
| July 5, 2011 |
Exhibit 99.5 Employee Call Script JOSH: ? Good morning and thank you for joining us. ? By now you should all be aware of this morning?s announcement that our Board has unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. ? Nino and I wanted to take a few minutes to speak with you all personally and share some additional information about this exciting announcement. ? |
|
| July 5, 2011 |
Exhibit 99.1 July 5, 2011 Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. We?d like to share some additional information with you about today?s announcement. By partnering with TPG Capital, Immucor will become a privately held company that is backed by the scalable resources of a global investment fi |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| July 5, 2011 |
Exhibit 99.6 Senior Manager Talking Points What we announced: ? Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital. ? TPG Capital is a well-respected global investment company that seeks out well-managed, fundamentally solid businesses for long-term investments. Benefits of transaction: ? By partnering with TPG Capital, Immucor wi |
|
| July 5, 2011 |
Dear Scientific Advisory Board Member, EX-99.8 9 ex99-8.htm EXHIBIT 99.8 Exhibit 99.8 Dear Scientific Advisory Board Member, Today, Immucor announced that the Company’s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately held company. Enclosed is the press release we issued announcing the transaction. We are writing to |
|
| July 5, 2011 |
Dear Valued Immucor Distributor: Exhibit 99.7 Dear Valued Immucor Distributor: Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company. Enclosed is the press release we issued announcing the transaction. TPG Capital is a well-respected private equity firm with |
|
| July 5, 2011 |
Exhibit 99.2 Dear Valued Immucor Customer: Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company that remains solely dedicated to transfusion medicine. Enclosed is the press release we issued announcing the transaction. TPG Ca |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| July 5, 2011 |
Dear Scientific Advisory Board Member, Exhibit 99.8 Dear Scientific Advisory Board Member, Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately held company. Enclosed is the press release we issued announcing the transaction. We are writing to personally inform you about the p |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| July 5, 2011 |
Exhibit 99.3 Employee FAQ 1. What was announced today? Today we announced that our Board of Directors has approved the sale of Immucor to TPG Capital, a leading investment firm. We believe partnering with TPG Capital will help fuel Immucor?s growth and strengthen our leadership position in the global marketplace for transfusion medicine. 2. Who is TPG Capital? TPG Capital is a well-respected globa |
|
| July 5, 2011 |
Exhibit 99.4 Dear Valued Immucor Supplier: Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company. Enclosed is the press release we issued announcing the transaction. TPG Capital is a well-respected private equity firm with ext |
|
| July 5, 2011 |
Exhibit 99.5 Employee Call Script JOSH: · Good morning and thank you for joining us. · By now you should all be aware of this morning’s announcement that our Board has unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. · Nino and I wanted to take a few minutes to speak with you all personally and share some additional information about this exciting announcement. · |
|
| July 5, 2011 |
Exhibit 99.4 Dear Valued Immucor Supplier: Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company. Enclosed is the press release we issued announcing the transaction. TPG Capital is a well-respected private equity firm with ext |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC. (Name of Subject Company) IMMUCOR, INC. (Name of Person Filing Statement) Common Stock, par value $0.10 per share (Title of Class of Securities) 452526106 (CUSIP Number of Class of Sec |
|
| July 5, 2011 |
Dear Valued Immucor Distributor: Exhibit 99.7 Dear Valued Immucor Distributor: Today, Immucor announced that the Company’s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company. Enclosed is the press release we issued announcing the transaction. TPG Capital is a well-respected private equity firm with |
|
| July 5, 2011 |
EX-99.1 4 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY TPG CAPITAL Immucor Shareholders to Receive $27.00 per Share in Cash; Fully Diluted Equity Value of $1.973 Billion NORCROSS, Ga., July 05, 2011 – Immucor, Inc. (Nasdaq: BLUD) (the "Company"), a global leader in providing automated instrument-reagent systems to the blood t |
|
| July 5, 2011 |
EX-2.1 2 ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among IMMUCOR, INC., IVD HOLDINGS INC. and IVD ACQUISITION CORPORATION Dated July 2, 2011 TABLE OF CONTENTS Page ARTICLE I THE OFFER AND THE MERGER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions 5 Section 1.3. Directors 6 Section 1.4. Top-Up Option 7 Section 1.5. The Merger 9 Section 1.6. Closing 9 Section 1.7. Effect |
|
| July 5, 2011 |
Exhibit 99.2 Dear Valued Immucor Customer: Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. When this transaction is completed, Immucor will become a privately-held company that remains solely dedicated to transfusion medicine. Enclosed is the press release we issued announcing the transaction. TPG Ca |
|
| July 5, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE IMMUCOR ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY TPG CAPITAL Immucor Shareholders to Receive $27.00 per Share in Cash; Fully Diluted Equity Value of $1.973 Billion NORCROSS, Ga., July 05, 2011 ? Immucor, Inc. (Nasdaq: BLUD) (the "Company"), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announc |
|
| July 5, 2011 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among IMMUCOR, INC., IVD HOLDINGS INC. and IVD ACQUISITION CORPORATION Dated July 2, 2011 TABLE OF CONTENTS Page ARTICLE I THE OFFER AND THE MERGER 2 Section 1.1. The Offer 2 Section 1.2. Company Actions 5 Section 1.3. Directors 6 Section 1.4. Top-Up Option 7 Section 1.5. The Merger 9 Section 1.6. Closing 9 Section 1.7. Effective Time 10 ARTICLE II ARTICLES |
|
| July 5, 2011 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 IMMUCOR, INC (Exact Name of Registrant as Specified in Its Charter) Georgia 22-2408354 (State of Incorporation or Organization) (IRS Employer Identification No.) 3130 Gateway Drive, Norcross, Georgia 30071 ( |
|
| July 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| July 5, 2011 |
AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDER RIGHTS AGREEMENT Exhibit 4.1 AMENDMENT NO. 2 TO AMENDED AND RESTATED SHAREHOLDER RIGHTS AGREEMENT This Amendment No. 2 to Amended and Restated Shareholder Rights Agreement, which is effective on July 2, 2011 (the ?Amendment?), is between Immucor, Inc., a Georgia corporation (the ?Company?), and Computershare Trust Company, N.A. (the ?Rights Agent?). RECITALS: WHEREAS, the Board of Directors of the Company previous |
|
| July 5, 2011 |
Exhibit 99.1 July 5, 2011 Today, Immucor announced that the Company?s Board of Directors unanimously approved the sale of Immucor to TPG Capital, a leading investment firm. We?d like to share some additional information with you about today?s announcement. By partnering with TPG Capital, Immucor will become a privately held company that is backed by the scalable resources of a global investment fi |
|
| June 15, 2011 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT (the ?Agreement?), made and entered into as of the 10th day of June, 2011 (the ?Restatement Date?), by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30071 (herein referred to as the ?Company?), and Philip H. Mo?se, residing at 948 Oakdale Road, Atlanta, Georg |
|
| June 15, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| June 15, 2011 |
FY 2012 BONUS AND LONG-TERM INCENTIVE PLAN Executive Officers Exhibit 10.1 FY 2012 BONUS AND LONG-TERM INCENTIVE PLAN Executive Officers Bonus Plan This is a bonus plan for all officers named as executive officers by the Company?s Board of Directors (currently the CEO, CFO and General Counsel). All bonuses will be based on the Company achieving specified FY 2012 net income goals and other corporate goals established by the Compensation Committee of the Board |
|
| June 15, 2011 |
Exhibit 10.2 Execution Copy AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT (the ?Agreement?), made and entered into as of the 10th day of June, 2011 (the ?Restatement Date?), by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30071 (herein referred to as the ?Company?), and Richard A. Flynt, residing at 12180 Oak Hollow |
|
| June 13, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| June 13, 2011 |
Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770-441-2051 Immucor CEO Dr. Gioacchino De Chirico Announces Retirement; Board Appoints Joshua H. Levine CEO and Director NORCROSS, Ga., June 12, 2011 ? Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that Dr. Gioacchino De Chirico has steppe |
|
| June 13, 2011 |
Exhibit 10.1 Execution Copy EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30071 (the ?Company?), and Joshua H. Levine ( ?Executive?). The parties hereto desire to enter into an agreement for the Company?s employment of Executive on the |
|
| June 13, 2011 |
EX-10.2 3 ex10-2.htm INDEMNIFICATION AGREEMENT Exhibit 10.2 INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT, made and entered into as of June 10, 2011 ("Agreement"), by and between Immucor, Inc., a Georgia corporation (the "Corporation"), and Joshua H. Levine ("Indemnitee"). WHEREAS, the Board of Directors of the Corporation (the "Board") has determined that the ability to attract and ret |
|
| April 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2011 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| April 7, 2011 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2011 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| April 6, 2011 |
Immucor Announces Fiscal Third Quarter Results EXHIBIT 99.1 Immucor Announces Fiscal Third Quarter Results NORCROSS, Ga., April 6, 2011 (GLOBE NEWSWIRE) - Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2011 third quarter ended February 28, 2011. Highlights Revenue for the third quarter of fiscal 2011 was $83.3 mill |
|
| April 6, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 6, 2011 Immucor, Inc. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: * Immucor, Inc (Name of Issuer) Common Stock (Title of Class of Securities) 452526106 (CUSIP Number) 12/31/2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed. |
|
| February 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 02)* Immucor Inc. (Name of Issuer) Common (Title of Class of Securities) 452526106 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| January 7, 2011 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: November 30, 2010 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| January 6, 2011 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 6, 2011 Immucor, Inc. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| January 6, 2011 |
Immucor Announces Fiscal Second Quarter Results EXHIBIT 99.1 Immucor Announces Fiscal Second Quarter Results NORCROSS, Ga., Jan. 6, 2011 (GLOBE NEWSWIRE) - Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2011 second quarter ended November 30, 2010. Highlights Revenue for the second quarter of fiscal 2011 was $81.5 mi |
|
| November 29, 2010 |
Immucor to Present at the Piper Jaffray Health Care Conference EXHIBIT 99.1 Immucor to Present at the Piper Jaffray Health Care Conference NORCROSS, Ga., Nov. 29, 2010 (GLOBE NEWSWIRE) - Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that access to its presentation at the 22nd Annual Piper Jaffray Health Care Conference in New York, NY will be available via a li |
|
| November 29, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2010 Immucor, Inc. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 16, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| November 8, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| November 8, 2010 |
U.S. Department of Justice Closes its Investigation of Immucor EXHIBIT 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770-441-2051 U.S. Department of Justice Closes its Investigation of Immucor NORCROSS, Ga., November 8, 2010 ? Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that the United States Department of Justice, Antitrust Division, has informed Immuc |
|
| October 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporatio |
|
| October 7, 2010 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: August 31, 2010 OR o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| October 6, 2010 |
Immucor Announces Fiscal First Quarter Results EXHIBIT 99.1 Immucor Announces Fiscal First Quarter Results NORCROSS, Ga., Oct. 6, 2010 (GLOBE NEWSWIRE) - Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2011 first quarter ended August 31, 2010. Highlights Revenue for the first quarter of fiscal 2011 was $83.6 million |
|
| October 6, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 6, 2010 Immucor, Inc. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| September 24, 2010 |
SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to Rule 14a-12 IMMUCOR, INC. |
|
| September 24, 2010 |
SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, For Use of the Commission Only (as permitted by Rule 14a-6 (e) (2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to Rule 14a-12 IMMUCOR, INC. |
|
| August 17, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation |
|
| August 17, 2010 |
AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the ?Agreement?), dated as of August 1, 2010, is made and entered into by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30071 (herein referred to as ?Employer? or the ?Company?), and Geoffrey Crouse, residing at 3230 Wood Vall |
|
| July 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| July 26, 2010 |
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 COOPERATION AGREEMENT July 23, 2010 Mr. Mason Morfit ValueAct Capital 435 Pacific Avenue Fourth Floor San Francisco, CA 94133 Re: Cooperation Agreement Dear Mason: Based upon the recommendation of the Governance Committee (the “Governance Committee”) of the board of directors (the “Board”) of Immucor, Inc. (the “Company”), and having received your con |
|
| July 26, 2010 |
Immucor Appoints G. Mason Morfit to Board of Directors Exhibit 99.1 FOR IMMEDIATE RELEASE CONTACT: Michele Howard 770-441-2051 Immucor Appoints G. Mason Morfit to Board of Directors NORCROSS, Ga., July 26, 2010 ? Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today announced that G. Mason Morfit has been appointed to its board of directors as a new independent director |
|
| July 26, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF x THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMU |
|
| July 23, 2010 |
Exhibit 21 Subsidiaries of Registrant Subsidiary Jurisdiction of Organization Immucor Medizinische Diagnostik GmbH Germany Immucor Italia S. |
|
| July 23, 2010 |
Exhibit 99.1 Summary of Lawsuits 1. The following lawsuits were originally filed in the districts listed below. All of the cases filed outside of the Eastern District of Pennsylvania, except that filed by Ivy Creek of Tallapoosa, LLC, d/b/a Lake Martin Community Hospital, were subsequently transferred to the United States District Court for the Eastern District of Pennsylvania pursuant to orders e |
|
| July 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF x THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended May 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-14820 IMMUCOR, INC. (Exact n |
|
| July 22, 2010 |
Immucor Announces Fiscal Fourth Quarter Results EXHIBIT 99.1 Immucor Announces Fiscal Fourth Quarter Results NORCROSS, Ga., July 22, 2010 (GLOBE NEWSWIRE) - Immucor, Inc. (Nasdaq:BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for its fiscal 2010 fourth quarter ended May 31, 2010. Highlights Revenue for the fourth quarter of fiscal 2010 was $82.9 millio |
|
| July 22, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2010 Immucor, Inc. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| May 14, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) F |
|
| April 23, 2010 |
Exhibit 10.1 IMMUCOR, INC. FY 2011 Bonus Plan and Long-Term Incentive Plan For Executive Officers Adopted April 19, 2010 Bonus Plan This is a bonus plan for all officers named as executive officers by the Company?s Board of Directors (currently the CEO, COO, CSO, CFO and General Counsel). All bonuses will be based on the Company achieving specified FY 2011 net income goals and other corporate goal |
|
| April 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction (Commission (IRS Employer of incorporation) |
|
| April 1, 2010 |
FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q United States Securities and Exchange Commission Washington, D. C. 20549 (Mark One) X Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: February 28, 2010 OR Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-14820 IMMUCOR, INC. (Exact name of registrant as |
|
| March 31, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2010 IMMUCOR, INC. (Exact name of registrant as specified in its charter) Georgia 0-14820 22-2408354 (State or other jurisdiction of incorporation) (Commission File Number) |
